Innovation Cancer Fund - Personalized Cancer Medicine

The medical and research heads at Jewish General Hospital determine the areas of highest priority and allocate the funds from the Innovation Cancer Fund to that specific cancer, to ensure crucial momentum can continue for their current programs.

Personalized Cancer Medicine is a multi-faceted, integrated approach involves finding the right treatment, for the right patient, at the right time. Our focus is to detect cancer research, diagnose with more precision and target treatment for each individual and support patients and their families throughout the cancer journey.

Genitourinary Cancer including Prostate Cancer

Prostate:

Prostate cancer is the most common cancer among Canadian men (excluding non-melanoma skin cancers). It is the 3rd leading cause of death from cancer in men in Canada.

It is estimated that in 2015:

  • 24,000 men will be diagnosed with prostate cancer. This represents 24% of all new cancer cases in men in 2015.
  • 4,100 men will die from prostate cancer. This represents 10% of all cancer deaths in men in 2015.
  • On average, 66 Canadian men will be diagnosed with prostate cancer every day.
  • On average, 11 Canadian men will die from prostate cancer every day.

Testicular

It is estimated that in 2015:

  • 1,050 Canadian men will be diagnosed with testicular cancer.

Actual mortality is available for 2010:

  • 40 men died from testicular cancer in Canada.

Bladder

It is estimated that in 2015:

  • 8,300 Canadians will be diagnosed with bladder cancer.
  • 2,300 Canadians will die from bladder cancer.
  • 6,200 men will be diagnosed with bladder cancer and 1,600 will die from it.
  • 2,100 women will be diagnosed with bladder cancer and 680 will die from it.

Kidney

It is estimated that in 2015:

  • 6,200 Canadians will be diagnosed with kidney cancer.
  • 1,800 Canadians will die from kidney cancer.
  • 3,900 men will be diagnosed with kidney cancer and 1,150 will die from it.
  • 2,300 women will be diagnosed with kidney cancer and 660 will die from it.

Breast & Gynecological Cancers:

For women in Quebec, breast cancer is the most frequently diagnosed type of cancer. It is estimated 1 in 9 Canadian women are expected to develop breast cancer in their lifetime and 1 in 30 will die from it. 1,500 Canadian women will be diagnosed with cervical cancer, 6,300 will be diagnosed with uterine cancer, and 2,800 will be diagnosed with ovarian cancer.

The Breast Cancer Service at the Segal Cancer Centre is internationally renowned and has been a long preoccupation of the Jewish General Hospital. Our services include prevention programs, one of the Quebec-designated screening and early diagnostic centres (CRID), fully integrated surgical-medical-radiation oncology services, expertise in breast reconstruction, access to the very latest in treatment options, lymphedema program, genetics program and tumour registry. For more information go to: http://www.jgh.ca/en/breastcancerservice?mid=ctl00_LeftMenu_ctl00_TheMenu-menuItem002-subMenu-menuItem002

The Gynecologic Oncology program at the Segal Cancer Centre was established to concentrate exclusively on the study and treatment of gynecologic cancers, integrating prevention strategies, screening tools, detection methods, sophisticated diagnostic equipment, skillful pelvic and abdominal surgery, innovative chemotherapy protocols, hi-tech radiation therapy and best supportive care practices. Treatment of patients presenting with cancer of the vulva, vagina, cervix, uterus, fallopian tubes, ovaries, pelvic cancers or primary peritoneal carcinomas is being centralized by the team of gynecologic oncologists whose interdisciplinary approach allows for efficient and optimal patient care without the need for unnecessary and redundant examinations. For more visit: http://www.jgh.ca/en/gynecologiconcology?mid=ctl00_LeftMenu_ctl00_TheMenu-menuItem002-subMenu-menuItem008

Head & Neck Cancers

Approximately 4,300 Canadians are diagnosed with head and neck cancers every year.

The Head & Neck clinic sees patients with a variety of head and neck cancers including oral cavity, throat, vocal cords, salivary glands and thyroid. An inter-disciplinary team composed of head and neck surgeons, radiation therapists, medical oncologists, endocrinologists, speech therapists, dietitians, nurses, pathologists, social workers, dentists, plastic and reconstructive surgeons, physiotherapists, psychologists, neurosurgeons and thoracic surgeons work together to provide the patient with expert, comprehensive care from diagnosis and treatment through to rehabilitation and follow-up. Patients also have access to a number of clinical trials. For more information visit: http://www.jgh.ca/en/headandneckoncology

Lung Cancer

Lung cancer is the leading cancer-related cause of death, both among men and women. Nearly a third of all cancer deaths in Quebec that is 31% are due to lung cancer alone.

The Peter Brojde Lung Cancer Centre (PBLCC) is dedicated to the care of patients with lung cancer. The PBLCC, came into being thanks to the extraordinary generosity and vision of Peter Brojde’s wife and family. The Centre, which was officially opened in 2012, is situated in a purpose-built area on the 10th floor of the E-pavilion within the Segal Cancer Centre at the Jewish General Hospital. The PBLCC draws on philosophies and evidenced-based practices in oncology and supportive care while striving to include appropriate, selected treatments from traditional Chinese Medicine and other complementary therapies. The aim is to achieve the best results with anti-cancer treatments while helping minimise symptoms and improve quality of life, health and healing for all patients. The incorporation of complementary therapies is an important and valued aspect of our approach as we seek to offer care that is holistic and personalized to meet the needs of each patient and their family.

Research is an immensely important part of the founding concept for the PBLCC. Both clinical and laboratory research in all aspects of Lung Cancer care are vital if we are to achieve improvements in the success of treatments. For more information visit: http://www.jgh.ca/en/brojdelungcentre?mid=ctl00_LeftMenu_ctl00_TheMenu-menuItem000

Hematologic Cancers Including Leukemia & Lymphoma

It is estimated that 6,200 Canadians will be diagnosed with leukemia and 8,200 Canadians will be diagnosed with non-Hodgkin lymphoma in 2015.

The Division of Hematology-Oncology is responsible for the treatment of patients with cancers of the blood, bone marrow and lymphatic system. Diseases treated include acute and chronic leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma and multiple myeloma. The Division is also involved in a number of clinical trials in leukemia, lymphoma, multiple myeloma and Hodgkin’s disease aimed at increasing the cure rate and survival of patients with these diseases. For more information visit: http://www.jgh.ca/en/hematologiconcology

Gastrointestinal Cancers

It is estimated that in 2015, 3,400 Canadians will be diagnosed with some form of stomach cancer.

The Hereditary Gastrointestinal Cancer Clinic (GENGI) is a joint clinic run by Dr. Polymnia Galiatsatos (department of Gastroenterology) and Alexandra Volenik (department of Medical Genetics). It was set up to streamline and coordinate the care of individuals with hereditary gastrointestinal cancer syndromes. These syndromes predispose to a range of cancers and require complex and intensive surveillance protocols. For more information visit: http://www.jgh.ca/en/hereditarygastrointestinalcancerclinic

Skin Cancer

It is estimated that in 2015, 6,800 Canadians will be diagnosed with melanoma.

Dermatology Oncology serves as an interdisciplinary team evaluating and treating patients with all types of skin cancer. The Division of Dermatology is essential to the diagnosis and treatment of cancer, serving both as a primary dermatological malignancy treatment centre and as an adjunctive diagnostic centre aiding in the diagnosis of other malignancies. Dermatology is often called upon by the Department of Oncology to perform biopsies of peculiar lesions that are malignant, enabling patients to undergo chemotherapy at a much earlier stage. In addition, dermatology is also used for staging to determine the extent of patients’ tumors and for planning the course of radiotherapy for patients with superficial cutaneous T-Cell and B-Cell lymphomas. For more information visit: http://www.jgh.ca/en/dermatologiconcology

Adolescents & Young Adults Oncology Program

The experience of young adults with cancer is often very different from that of other cancer patients. Caught between childhood and adulthood, they face medical and psychological challenges that require special attention. This stage of life also presents unique emotional and psychological challenges that are further complicated by having to contend with this disease. The Adolescent and Young Adult Oncology Program was established in 2003 as a joint venture between the McGill University Departments of Oncology and Medicine, and addresses the needs of cancer patients between the ages of 18-39. The age criteria is based on the recommendations of the National Cancer Institute of Canada. The program has a clinic at both the Segal Cancer Centre as well as at the MUHC-Royal Victoria Hospital.

The goals of Adolescent and Young Adult Oncology include: 
To provide optimal multidisciplinary care to this unique patient population, that requires a distinctive treatment approach. To register more adolescents and young adults in multi-centre research protocols and projects, at the national and international levels. To develop and participate in in-house protocols for this patient group. To improve the quality of teaching and research in this field of cancer therapy.5. To improve patient access to social services, and psychological and psychiatric support. For more information visit: http://www.jgh.ca/en/adolescentandyoungadultoncologyprogram

Cancer Nutrition & Rehabilitation Program

The McGill Cancer Nutrition-Rehabilitation Program is a highly innovative program which was initiated in 2002 by Dr. Neil MacDonald, through the McGill University, Department of Oncology. The Program, which has clinics at both the Segal Cancer Centre and the Royal Victoria Hospital, combines both nutritional counseling and physical rehabilitation to help combat the symptoms of poor appetite, weight loss, diminished function and fatigue which are common problems associated with cancer. For more complete information about the Program's history, goals, clinic sites and academic pursuits, please refer to the CNR Program website.

The CNR clinic has close ties with Hope & Cope which provides a wide range of psychosocial support and educational programs for cancer patients. One of the CNR dietitians, Nelda Swinton, regularly gives cooking and nutrition classes to cancer patients and cancer survivors at the JGH Hope & Cope Wellness Centre located close to the hospital. In addition, Anh-Thi Tran holds regular Qi-Gong classes for cancer patients at the Centre. Furthermore, patients leaving active CNR follow-up are encouraged to engage with the Wellness Centre facilities independently for on-going exercise and psychosocial support as appropriate.

Cancer Genetics Program

Hereditary cancer work and research has been a very important feature of cancer prevention at the Jewish General Hospital in the last decade. The Jewish General Hospital of McGill University, the Stroll Family Cancer Prevention Centre provides consultation services with a team of Cancer Geneticists and specialized Genetic Counsellors. For more information visit: http://www.jgh.ca/en/geneticsgeneralinformation